Status:
COMPLETED
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Lead Sponsor:
Changhai Hospital
Conditions:
Pancreatic Neuroendocrine Tumor G2
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Adjuvant therapy in pancreatic neuroendocrine tumors (pNETs) after radical resection lacks evidence-based data and is controversial. Real-world data were clustered to validate whether the long-acting ...
Detailed Description
Adjuvant therapy for pNETs was proposed as an unmet clinical need by the European Neuroendocrine Tumor Society Group in 2016.1The Clinical Practice Guidelines for pNETs in China recommended initiation...
Eligibility Criteria
Inclusion
- pNETs lesions pathologically classified as WHO grade 2
- Complete surgical resection (R0 or R1 was achieved)
- Adjuvant treatment was performed within 12 weeks after surgery
Exclusion
- Stage IV
- Other oncological history
- Previous antineoplastic systemic therapy
- Lack of information/details on recurrence or death.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
411 Patients enrolled
Trial Details
Trial ID
NCT06080204
Start Date
March 1 2008
End Date
April 1 2020
Last Update
October 18 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.